← Back to All Filings

Castle Biosciences COO Sells $390K in Company Stock

Low SignificanceNovember 4, 2025 at 9:02:48 PM EST

CASTLE BIOSCIENCES INC

$CSTL4/ACIK: 0001447362

Subscribe to track CSTL

Premium users can add ticker alerts and receive realtime notification updates.

Filing Summary

Castle Biosciences COO Sells $390K in Company Stock

Company: CASTLE BIOSCIENCES INC (CSTL) Form: 4/A | Filed: 2025-11-04 Significance: Low

Insider: Oelschlager Kristen M Title: Chief Operating Officer | Relationship: Officer

Transaction: • Type: Sale • Shares: 18,007 • Price: $21.69 • Value: $390,432 • Owned After: 153,861 (Direct & Indirect)

Key Insight: The COO sold shares valued at $390k, representing less than 0.1% of the company's shares outstanding. This amended filing corrects the ownership from direct to indirect.

Market Context: The transaction size is minor relative to the company's $740M market cap, indicating low market impact.

Comprehensive Analysis

SEC Filing Analysis: CASTLE BIOSCIENCES INC (CSTL)

Executive Summary

  • Trading Significance: Low
  • Key Takeaway: The Chief Operating Officer, Kristen M. Oelschlager, executed an indirect sale of common stock valued at approximately $390,000.
  • Market Impact: The transaction is of low materiality, representing a negligible percentage of the company's market capitalization and shares outstanding.

Company Information

FieldValue
CompanyCASTLE BIOSCIENCES INC
Ticker SymbolCSTL
CIK0001447362
IndustrySERVICES-MEDICAL LABORATORIES

Insider Information

FieldValue
NameOelschlager Kristen M
CIK0001856565
Title/PositionChief Operating Officer
RelationshipOfficer

Transaction Details

FieldValue
Form Type4/A
Transaction Date2025-08-27
Transaction CodeS (Sale)
Security TypeCommon Stock
Shares Involved18,007
Price Per Share$21.69
Total Value$390,431.83
Shares Owned After153,861 (Total Direct & Indirect)
Ownership TypeIndirect

Financial Impact Assessment

Transaction Materiality

MetricValue
Transaction Value$390,431.83
% of Market Cap0.053%
Shares Transacted18,007
% of Shares Outstanding0.062%
Post-Transaction Ownership153,861 shares (0.53% of outstanding)
Materiality AssessmentLow

Impact Evaluation

  • Market Cap Context: For a company with a market capitalization of $740 million, this $390k sale is not financially significant.
  • Ownership Concentration: The sale reduced the COO's holdings by approximately 10.5%, a minor adjustment to her overall position. Her remaining stake is 0.53% of all outstanding shares.
  • Transaction Significance: The transaction falls well below the thresholds for moderate or high significance (<0.1% of market cap and <0.1% of shares outstanding).

Market Impact Analysis

Stock Impact Prediction

  • Direction: Neutral
  • Reasoning: The sale is too small relative to the company's market capitalization and public float to have a meaningful impact on the stock price. It appears to be a routine diversification or liquidity event for the insider.

Volume & Sentiment

  • Expected Volume Impact: Negligible. The transaction size is unlikely to influence trading volume.
  • Sentiment Indicator: Neutral. This is a small, routine insider sale with no clear bearish signal.

Additional Context

Transaction Notes

  • Special Circumstances: This Form 4/A was filed to amend a previous report, correcting the nature of the sale from direct to indirect (via The Fritz Shorter Trust) and updating the post-transaction holding amounts. The insider retains beneficial ownership and investment power over the trust's shares.
Topics:#SECFiling#InsiderTrading#CSTL#CastleBiosciences#Form4#InsiderSell#StockMarket#MarketAnalysis

Get Real-Time Alerts

Join our community to receive instant notifications when high-significance filings are published

Important Disclaimer

This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.

Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.